A share price of Arcus Biosciences Inc [RCUS] is currently trading at $17.29, up 1.05%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The RCUS shares have gain 11.98% over the last week, with a monthly amount glided 9.92%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Arcus Biosciences Inc [NYSE: RCUS] stock has seen the most recent analyst activity on October 21, 2024, when H.C. Wainwright initiated its Neutral rating and assigned the stock a price target of $20. Previously, Wells Fargo started tracking the stock with Overweight rating on October 08, 2024, and set its price target to $29. On November 18, 2022, BofA Securities initiated with a Neutral rating and assigned a price target of $33 on the stock. Morgan Stanley started tracking the stock assigning a Overweight rating and suggested a price target of $40 on October 11, 2022. Berenberg started tracking with a Buy rating for this stock on November 24, 2020, and assigned it a price target of $50. In a note dated November 23, 2020, Evercore ISI initiated an Outperform rating.
Arcus Biosciences Inc experienced fluctuations in its stock price throughout the past year between $13.52 and $20.31. Currently, Wall Street analysts expect the stock to reach $31.71 within the next 12 months. Arcus Biosciences Inc [NYSE: RCUS] shares were valued at $17.29 at the most recent close of the market. An investor can expect a potential return of 83.4% based on the average RCUS price forecast.
Analyzing the RCUS fundamentals
Trailing Twelve Months sales for Arcus Biosciences Inc [NYSE:RCUS] were 263.00M which represents 50.00% growth. Gross Profit Margin for this corporation currently stands at 0.96% with Operating Profit Margin at -1.21%, Pretax Profit Margin comes in at -1.02%, and Net Profit Margin reading is -1.03%. To continue investigating profitability, this company’s Return on Assets is posted at -0.22, Equity is -0.46 and Total Capital is -0.31. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.08.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 16.80 points at the first support level, and at 16.32 for the second support level. However, for the 1st resistance point, the stock is sitting at 17.93, and for the 2nd resistance point, it is at 18.58.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Arcus Biosciences Inc [NYSE:RCUS] is 5.23. As well, the Quick Ratio is 5.23, while the Cash Ratio is 0.93. Considering the valuation of this stock, the price to sales ratio is 6.08, the price to book ratio is 2.80.
Transactions by insiders
Recent insider trading involved Azoy Alexander, Chief Accounting Officer, that happened on Dec 02 ’24 when 201.0 shares were sold. Chief Accounting Officer, Azoy Alexander completed a deal on Aug 13 ’24 to sell 1357.0 shares. Meanwhile, Chief Operating Officer Jarrett Jennifer sold 11551.0 shares on Mar 27 ’24.
